Welcome to our dedicated page for Kalvista Pharm SEC filings (Ticker: KALV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Analyzing a biotech filing packed with plasma kallikrein science can feel overwhelming. KalVista Pharmaceuticals’ 10-K routinely spans hundreds of pages covering cash burn, trial endpoints, and risk factors unique to rare-disease drug development. Finding when executives file Form 4 insider trades—or whether an 8-K flags a clinical setback—takes time most professionals don’t have.
Our platform solves this. Stock Titan’s AI reads every KalVista Pharmaceuticals annual report 10-K simplified and each KalVista Pharmaceuticals quarterly earnings report 10-Q filing the moment it hits EDGAR. It then serves plain-English summaries that answer the questions investors actually search for, like “understanding KalVista Pharmaceuticals SEC documents with AI” or “KalVista Pharmaceuticals earnings report filing analysis”. Need real-time alerts? We surface KalVista Pharmaceuticals Form 4 insider transactions real-time, highlight option exercises, and cross-link to KalVista Pharmaceuticals insider trading Form 4 transactions history so you can monitor sentiment before key readouts.
Beyond headline numbers, our reports map trial spending to pipeline stage, flag shelf-registration gestures that hint at future raises, and decode the jargon inside every KalVista Pharmaceuticals proxy statement executive compensation. You’ll also see concise breakdowns of material events—“KalVista Pharmaceuticals 8-K material events explained”—and alerts on KalVista Pharmaceuticals executive stock transactions Form 4. Whether you’re modeling cash runway or tracking the new Factor XIIa program, Stock Titan delivers the data, context, and AI-powered clarity you need—without wading through endless pages.
KalVista Pharmaceuticals (KALV) insider activity: Christopher Yea, the company’s Chief Development Officer and a director, received 3,125 restricted stock units (RSUs) that convert one-for-one into common shares upon settlement. The RSUs were reported as acquired upon vesting and increase the reporting person's contingent claim on 3,125 shares. To satisfy tax withholding when those RSUs settled, the reporting person sold 1,954 shares at $13.42 per share in a "sell-to-cover" transaction, which was not a discretionary sale. After these transactions the reporting person beneficially owned 132,052 common shares and continued to hold RSUs representing 34,375 underlying shares that vest quarterly at one-sixteenth of the total per quarter while service continues.
KalVista Pharmaceuticals insider filing: Chief Medical Officer Audhya Paul K. received 5,000 restricted stock units (RSUs) that vested and settled on 08/22/2025 and represent rights to 5,000 shares. Following that settlement the reporting person beneficially owned 124,841 shares. A subsequent sale of 2,336 shares occurred on 08/25/2025 at a price of $13.42 per share to satisfy tax withholding for the RSU vesting, leaving 122,505 shares beneficially owned. The RSUs vest quarterly at 1/16th of the total and the report shows 55,000 underlying RSUs in total.
Nicole Sweeny, Chief Commercial Officer of KalVista Pharmaceuticals (KALV), reported the vesting and settlement of restricted stock units and a subsequent sell-to-cover transaction. On 08/21/2025 she was issued 6,250 shares upon settlement of RSUs, increasing her beneficial ownership to 30,635 shares. On 08/22/2025 she sold 1,864 shares at $13.2228 per share to satisfy tax withholding obligations, leaving 28,771 shares beneficially owned. The filing explains each RSU converts to one share for no consideration and that RSUs vest at a rate of 1/16th of the award on each quarterly anniversary beginning May 21, 2025, subject to continued service.
Nicole Sweeny filed an initial Form 3 reporting her beneficial ownership in KalVista Pharmaceuticals, Inc. (KALV) in her role as Chief Commercial Officer and a director. She holds 100,000 RSUs granted with a vesting schedule that begins May 21, 2025, vesting 1/16th quarterly, and 80,000 RSUs granted with a vesting schedule that began August 22, 2024, vesting 1/16th quarterly. She also holds an employee stock option on 100,000 shares with a stated exercise price of $9.51 and a listed date of 07/24/2033 in the derivative table. The RSUs are described as contingent rights to receive one share upon settlement for no consideration. The Form 3 is signed by an attorney-in-fact, Benjamin Palleiko, dated 08/25/2025.
KalVista Pharmaceuticals insider filing: Christopher Yea, Chief Development Officer, received a grant of 3,750 restricted stock units (RSUs) on 08/21/2025 that convert 1-for-1 into common shares upon settlement for no consideration. After the grant, the reporting person beneficially owned 133,243 shares. On 08/22/2025 he sold 2,362 shares at an average price of $13.2228 to satisfy tax-withholding obligations from the RSU settlement, leaving 130,881 shares beneficially owned. The RSUs vest quarterly with 1/16th vesting on each quarterly anniversary beginning 05/21/2025, subject to continued service. The sale was described as a routine "sell to cover" for taxes and not a discretionary trade.
KalVista Pharmaceuticals (KALV) Chief Executive Officer and Director Benjamin L. Palleiko reported the vesting and settlement of 23,250 restricted stock units (RSUs) on 08/21/2025, each representing a contingent right to one share of common stock upon settlement for no consideration. Following the RSU settlement, the Form 4 shows the reporting person beneficially owned 397,798 shares. On 08/22/2025 the reporting person sold 10,940 shares at a reported price of $13.2228 per share to satisfy tax withholding obligations related to the RSU settlement, leaving 386,858 shares reported as beneficially owned after the sale.
The filing specifies the RSU vesting schedule: 1/16th of the total shares subject to the RSU vest on each quarterly anniversary beginning May 21, 2025, subject to continued service. The sale is described as a "sell-to-cover" to satisfy tax withholding and is not a discretionary transaction.
Audhya Paul K., Chief Medical Officer and director of KalVista Pharmaceuticals, reported equity transactions in the company in late August 2025. On 08/21/2025 the reporting person was issued 6,250 restricted stock units (RSUs) that convert one-for-one into common shares upon settlement, bringing beneficial ownership to 122,783 shares. On 08/22/2025 the reporting person sold 2,942 shares at $13.2228 per share, reducing beneficial ownership to 119,841 shares. The sale was a sell-to-cover transaction to satisfy tax withholding obligations related to the RSU vesting, not a discretionary sale. The RSU award vests in 1/16th increments each quarterly anniversary starting May 21, 2025, subject to continued service.
KalVista Pharmaceuticals, Inc. (KALV) is soliciting proxies for its 2025 Annual Meeting to be held virtually on October 1, 2025 at 1:00 p.m. ET. The Record Date for voting is August 6, 2025, with 50,339,823 shares of common stock outstanding as of that date. The Board asks shareholders to vote FOR election of the Class I director nominees (Proposal No. 1), FOR ratification of Deloitte & Touche LLP as independent auditor for the transition period ending December 31, 2025 (Proposal No. 2), and FOR the non-binding advisory approval of named executive officer compensation (Proposal No. 3). Proxy materials will be made available online around August 26, 2025, with instructions for requesting printed copies and access at the Company’s investor website.
Frazier-affiliated funds filed Amendment No. 6 to a Schedule 13D for KalVista Pharmaceuticals (KALV) updating beneficial ownership tables and correcting prior attributions. The filing reports specific share counts held directly by several Frazier vehicles: Frazier Life Sciences Public Fund, L.P. (FLSPF) holds 2,400,276 shares (4.8% of class), Frazier Life Sciences Public Overage Fund, L.P. holds 946,074 shares (1.9%), Frazier Life Sciences X, L.P. holds 1,156,869 shares (2.3%), and Frazier Life Sciences XI, L.P. holds 384,648 shares (0.8%). All percentages are calculated using 49,953,739 shares outstanding as of June 25, 2025 per the issuer's annual report.
The amendment clarifies voting and dispositive power: the reported holdings are shared voting/dispositive power for the listed Frazier entities and correct prior over-attributions to individual committee members or managers. It also states that, except as specified, the prior Schedule 13D and amendments remain unchanged and that the filing does not concede beneficial ownership or group status beyond what is expressly stated. A Joint Filing Agreement is referenced as Exhibit 99.1.
FAQ
What is the current stock price of Kalvista Pharm (KALV)?
What is the market cap of Kalvista Pharm (KALV)?
